Questcor price target raised to $69 from $59 at Oppenheimer After meeting with Questcor's management and ivnestors, Oppenheimer increased its target on the stock as the firm is nearly certain that the company will benefit from Medicaid reimbursement changes by early 2013. The firm expects the stock to become less volatile as investors become more comfortable with risks facing the company, and it believes that this reduced volatility will make the stock more attractive to investors. Oppenheimer maintains an Outperform rating on the shares.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.